CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 128 enrolled
Drug / intervention
Lexapro +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02516332
NCT02516332N/ACompleted

Exercise and Pharmacotherapy for Anxiety in Cardiac Patients

Duke University·interventional·Posted Aug 5, 2015·Updated Jun 11, 2021

In Brief

A clinical study evaluating Lexapro, Placebo, and 1 other intervention for Anxiety and Cardiovascular Disease. Completed, enrolled 128 participants across 1 site.

Detailed Summary

Coronary heart disease (CHD) is the leading cause of death in the United States; more than 600,000 Americans suffer a fatal cardiac event each year. Traditional CHD risk factors such as high blood pressure, smoking, and elevated cholesterol do not fully account for the timing and occurrence of CHD events and individuals with elevated levels of anxiety appear to have a greater risk of cardiovascular events. The present study will examine the impact of aerobic exercise and Lexapro in the treatment of anxiety and cardiovascular biomarkers among individuals with CHD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 5, 2015
Enrollment StartDec 1, 2015
Primary CompletionMay 1, 2020
Study CompletionMay 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 10.9 years ago

Interventions

Lexaprodrug

Placebodrug

Supervised Aerobic Exercisebehavioral